Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
22
×
deals
22
×
life sciences
national blog main
biotech
boston top stories
national top stories
san francisco blog main
fda
clinical trials
investing
san francisco top stories
startups
boston
new york blog main
new york top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
national
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
indiana blog main
indiana top stories
alzheimer's disease
novartis
What
medicines
bio
drug
new
roundup
therapeutics
ipo
research
biotech
cancer
deal
develop
fda
caught
developing
disease
gene
life
raised
roche
sciences
startup
treat
years
acquisitions
address
ago
alliance
amid
approval
based
big
billion
bombast
buy
called
candidate
ceo
companies
company
Language
unset
22
×
Current search:
unset
×
deals
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds